Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

By Yinghong Wang, Diana H. Wiesnoski, Beth A. Helmink, V. Gopalakrishnan, Kati Choi, H. Dupont, Zhi-Dong Jiang, Hamzah Abu-Sbeih, Christopher A. Sanchez, Chia-Chi Chang and 15 more. Nature Medicine, 2018

653 citations recorded by the source corpus.

Subfields: Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/c7cd4cfc75bfec18072faf3ff7352e4df2e9e21e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. Rob Knight
2. L. Zitvogel
3. J. Wargo

In Oncology

1. L. Zitvogel
2. J. Wargo

Citations in the corpus

• The microbiome and human cancer (2021, background): “FMT treats Clostridium difficile (now Clostridioides difficile) colitis effectively (140), with some efficacy in the treatment of immunotherapyassociated colitis (141).”
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021, background): “Fecal microbiota transplantation has also been demonstrated to achieve 75% efficacy in treating 15 refractory colitis cases.(81,82) Preliminary data suggest that GI toxicities are associated with improved survival and treatment outcomes in comparison to other immunotherapy treated patients.”
• Akkermansia muciniphila is a promising probiotic (2019, background): “However, the causal relationship between the microbes and host genomes is very complicated and needs to be further evaluated (Wang et al., 2018a,b).”